blockchain-healthcare
(3)
David Lazerson
David Lazerson is the co-founder and CEO of Briya, a healthcare technology company that connects hospitals, research institutions, and life sciences organizations so they can share de-identified, real-world patient data securely and in compliance with U.S. and European privacy rules. A physicist and cognitive scientist by training and a former Israeli military cyber operations officer, Lazerson built Briya on cryptography, federated learning, and zero-knowledge proofs, and in 2025 launched Briya AIRE, a clinical-grade AI research assistant that lets researchers ask questions in plain language instead of writing code.
Robert Chu
Robert Chu is the co-founder and CEO of Embleema, a New York-based clinical research platform that collects and generates regulatory-grade evidence to accelerate precision medicine. He founded the company in 2017 after nearly three decades in enterprise technology and life sciences data, including roles as Senior Vice President of Global Technology Solutions at IQVIA (formerly QuintilesIMS), where he ran a 1,400-person, $800M SaaS business, and prior leadership positions at IMS Health in France, China, and Asia Pacific, following 15+ years at IBM. Trained as an engineer at Ecole Polytechnique in Paris, he now works at the intersection of patient consent, blockchain, and clinical data collection, with Embleema partnering with pharma sponsors and the FDA on real-world evidence workflows.
Robert Page
Robert Page is the CEO and founder of Pulse Protocol (formerly MedRepublic), a Los Angeles healthcare marketplace and B2B SaaS platform that helps clinics and facilitators run medical-travel businesses - matching patients to vetted providers, automating coordination, payments and marketing. A global-health operator since 2000, he previously built MedToGo International, co-authored three industry guidebooks, took MedRepublic into TechCrunch Disrupt's top 25 startups of 2016, and graduated from Amplify LA's accelerator. His through-line is unglamorous but stubborn: transparent pricing, quality control, and giving patients real options.